Paul Capital Acquires Dyax Royalty Rights To Xyntha
Paul Capital Healthcare has acquired from Dyax Corp. (Nasdaq: DYAX) the rights to royalties and other payments related to the commercialization of Xyntha by Pfizer Inc. The deal is valued at $12 million, including a $10 million up-front payment. Xynthia is a recombinant factor VIII product for patients with hemophilia A.
20 April 2010•5 mins read
